LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of April 28, 2026, LLY stock price climbed to $874.00 with 2,188,995 million shares trading.

LLY has a beta of 0.51, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.03 to the broad based SPY ETF.

LLY has a market cap of $780.48 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $19 billion in Revenue and $7.54 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.58.

In the last 3 years, LLY traded as high as $1,133.95 and as low as $392.26.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, VUG, SPY.

LLY has underperformed the market in the last year with a price return of +0.3% while the SPY ETF gained +30.5%. LLY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.5% and -5.3%, respectively, while the SPY returned +2.6% and +2.5%, respectively.

LLY support price is $851.89 and resistance is $884.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.